Now in Primary Care
Quick Links
Intensive versus Conventional Glucose Control in Critically Ill Patients (NICE-SUGAR)
EBM, Landmark Research
This classic, often-cited article informs us that among patients in the ICU, intensive glucose control of 81-108 increased mortality as compared to a more liberal glucose target of <180. How have you applied the findings of this research to your…
STOP-IT: Is a Short Course of Antibiotics Adequate for Intraabdominal Infections?
EBM, Journal Club
Current antibiotic stewardship guidelines at Olive View recommend 4 days of antibiotics for intraabdominal infections once source control is achieved. Here is clinical evidence of this "short" duration of antibiotics.
Symptom-triggered versus Fixed-schedule Doses of Benzodiazepine for Alcohol Withdrawal
EBM, Landmark Research
The Ativan Protocal at Olive View is a symptom-based algorithm for treatment of alcohol withdrawal. Here's the evidence for use of the symptom-based CIWA scale to determine the dosing of lorazepam as compared to fixed dosing of benzodiazepine. Read the…
Speech Therapy
Noon Conference
What do speech pathologists do? Dysphagia and Aspiration Dysphagia and Aspiration Oral Care Oral Care Orders for Swallowing Swallow Studies Orders Cheat Sheet Speech Therapy Orders Cheat Thickened Liquids Thickened Liquids in Patients with Dysphagia
Venous Thromboembolism & Anticoagulation
Noon Conference
Test your smarts about VTE and Anticoagulation.
View the presentation linked here.
August 2018
This month's articles focus on pharmacotherapy for two common diseases in Cardiology and Nephrology: Heart Failure with Reduced Ejection Fraction (HFrEF) and Diabetic Nephropathy. COMET: Comparing beta-blocker to beta-blocker RENAAL: Addition of Angiotensin II receptor blockers (ARB) to antihypertensive therapy
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
EBM, Landmark Research
Clinical Question: As compared to placebo, does the angiotensin-II-receptor agonist (ARB) losartan delay progression to ESRD and improve mortality in patients with type 2 diabetes and nephropathy?